Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesus Gonzalo-Asensio

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Microbiology Spectrum|July 16, 2017
Breaking Transmission with Vaccines: The Case of TuberculosisJesus Gonzalo-Asensio, Nacho Aguilo, Dessislava Marinova, et al.
Frontiers in Immunology|January 13, 2018
MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB EpidemicJesus Gonzalo-Asensio, Dessislava Marinova, Carlos Martin, et al.
Expert Review of Vaccines|April 28, 2017
MTBVAC from discovery to clinical trials in tuberculosis-endemic countriesDessislava Marinova, Jesus Gonzalo-Asensio, Nacho Aguilo, et al.
Expert Review of Vaccines|November 8, 2013
Recent developments in tuberculosis vaccinesDessislava Marinova, Jesus Gonzalo-Asensio, Nacho Aguilo, et al.
Nature Communications|July 15, 2017
Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosisNacho Aguilo, Jesus Gonzalo-Asensio, Samuel Alvarez-Arguedas, et al.
Ebiomedicine|March 12, 2021
BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studiesEsther Broset, Jacobo Pardo-Seco, Alex I Kanno, et al.
Plos Pathogens|July 14, 2023
Natural mutations in the sensor kinase of the PhoPR two-component regulatory system modulate virulence of ancestor-like tuberculosis bacilliWladimir Malaga, Delphine Payros, Eva Meunier, et al.
Vaccine|August 23, 2013
Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trialsAinhoa Arbues, Juan I Aguilo, Jesus Gonzalo-Asensio, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Microbiology Spectrum|July 16, 2017
Breaking Transmission with Vaccines: The Case of TuberculosisJesus Gonzalo-Asensio, Nacho Aguilo, Dessislava Marinova, et al.
Frontiers in Immunology|January 13, 2018
MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB EpidemicJesus Gonzalo-Asensio, Dessislava Marinova, Carlos Martin, et al.
Expert Review of Vaccines|April 28, 2017
MTBVAC from discovery to clinical trials in tuberculosis-endemic countriesDessislava Marinova, Jesus Gonzalo-Asensio, Nacho Aguilo, et al.
Expert Review of Vaccines|November 8, 2013
Recent developments in tuberculosis vaccinesDessislava Marinova, Jesus Gonzalo-Asensio, Nacho Aguilo, et al.
Nature Communications|July 15, 2017
Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosisNacho Aguilo, Jesus Gonzalo-Asensio, Samuel Alvarez-Arguedas, et al.
Ebiomedicine|March 12, 2021
BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studiesEsther Broset, Jacobo Pardo-Seco, Alex I Kanno, et al.
Plos Pathogens|July 14, 2023
Natural mutations in the sensor kinase of the PhoPR two-component regulatory system modulate virulence of ancestor-like tuberculosis bacilliWladimir Malaga, Delphine Payros, Eva Meunier, et al.
Vaccine|August 23, 2013
Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trialsAinhoa Arbues, Juan I Aguilo, Jesus Gonzalo-Asensio, et al.
Pageof 1